Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program

The International Journal on Drug Policy
Alain H LitwinRobert J Roose

Abstract

People who inject drugs (PWID) constitute 10 million people globally with hepatitis C virus, including many opioid agonist treatment patients. Little data exist describing clinical outcomes for patients receiving HCV treatment with direct-acting antiviral agents (DAAs) in opioid agonist treatment settings. In this retrospective observational study, we describe clinical outcomes for 50 genotype-1 patients receiving HCV treatment with triple therapy: telaprevir (n=42) or boceprevir (n=8) in combination with pegylated interferon and ribavirin on-site in an opioid agonist treatment program. Overall, 70% achieved an end of treatment response (ETR) and 62% achieved a sustained virological response (SVR). These treatment outcomes are nearly equivalent to previously published HCV outcomes shown in registration trials, despite high percentages of recent drug use prior to treatment (52%), ongoing drug use during treatment (45%) and psychiatric comorbidity (86%). Only 12% (n=6) discontinued antiviral treatment early for non-virological reasons. Four patients received a blood transfusion, and one discontinued telaprevir due to severe rash. These data demonstrate that on-site HCV treatment with direct-acting antiviral agents is effective in...Continue Reading

References

Oct 13, 2000·American Journal of Public Health·J B WongT Poynard
Jul 21, 2001·The New England Journal of Medicine·B R EdlinB Lo
Jul 21, 2001·The New England Journal of Medicine·G L Davis, J R Rodrigue
Mar 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alain H LitwinMarc N Gourevitch
Jul 11, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Margaret HellardJudy Gold
Dec 3, 2009·Journal of the International Association of Physicians in AIDS Care : JIAPAC·Seth C KalichmanChauncey Cherry
Mar 5, 2011·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Apr 1, 2011·The New England Journal of Medicine·Bruce R BaconUNKNOWN HCV RESPOND-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Sep 8, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for Study of Liver Diseases
Oct 6, 2012·Journal of Substance Abuse Treatment·Melissa R SteinAlain H Litwin
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rositsa B DimovaAndrew H Talal
Aug 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Geert RobaeysUNKNOWN International Network on Hepatitis in Substance Users
Oct 30, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Maryam AlaviJason Grebely
Dec 23, 2014·Emerging Infectious Diseases·Harish MoorjaniAnne C Spaulding
Apr 26, 2015·Journal of Hepatology·UNKNOWN European Association for Study of Liver
Jun 26, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·UNKNOWN AASLD/IDSA HCV Guidance Panel
Aug 10, 2015·The International Journal on Drug Policy·Jason GrebelyUNKNOWN International Network for Hepatitis in Substance Users
Aug 19, 2015·The International Journal on Drug Policy·Jason GrebelyUNKNOWN International Network for Hepatitis in Substance Users

❮ Previous
Next ❯

Citations

Jan 11, 2016·The International Journal on Drug Policy·Jason GrebelyUNKNOWN im Namen vom International Network on Hepatitis care in Substance Users
Aug 10, 2015·The International Journal on Drug Policy·Jason GrebelyUNKNOWN International Network for Hepatitis in Substance Users
Aug 19, 2015·The International Journal on Drug Policy·Jason GrebelyUNKNOWN International Network for Hepatitis in Substance Users
Aug 10, 2015·The International Journal on Drug Policy·Jason GrebelyUNKNOWN International Network for Hepatitis in Substance Users
Nov 2, 2019·Australian Health Review : a Publication of the Australian Hospital Association·Davoud PourmarziGerard FitzGerald
Jul 14, 2017·Addictive Disorders & Their Treatment·Stevan A GonzalezAndrew H Talal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Liver International : Official Journal of the International Association for the Study of the Liver
Marc BourlièreJean Pierre Bronowicki
Expert Opinion on Investigational Drugs
Sudeep TanwarGeoffrey M Dusheiko
Clinical and Translational Medicine
Tatsuo KandaMasao Omata
Deutsche medizinische Wochenschrift
C Neumann-HaefelinR Thimme
© 2021 Meta ULC. All rights reserved